CARA Therapeutics Inc. (CARA)

12.34
NASDAQ : Health Technology
Prev Close 12.34
Day Low/High 12.09 / 12.39
52 Wk Low/High 11.11 / 28.50
Avg Volume 934.10K
Exchange NASDAQ
Shares Outstanding 32.61M
Market Cap 402.39M
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Take-Two Interactive, Constellation Brands: 'Mad Money' Lightning Round

Take-Two Interactive, Constellation Brands: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Take-Two Interactive, Cronos Group, Constellation Brands, Wells Fargo, Cara Therapeutics, AK Steel Holding Corp., and TrueCar.

Cara Therapeutics Becomes Oversold (CARA)

Cara Therapeutics Becomes Oversold (CARA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Cara Therapeutics Reports Fourth Quarter And Full Year 2017 Financial Results

Cara Therapeutics Reports Fourth Quarter And Full Year 2017 Financial Results

Conference call today at 4:30 p.m. ET

There's Plenty of Positive Action But It's a Little Overheated

There's Plenty of Positive Action But It's a Little Overheated

I'll be watching for entry points to develop this afternoon.

There's No Big Rush for the Indices at this Point

There's No Big Rush for the Indices at this Point

The best way to deal with the struggling market is selective stock picking and good defense.

Buying Opportunities Present Themselves; Wells Fargo Directors to Leave -- ICYMI

Buying Opportunities Present Themselves; Wells Fargo Directors to Leave -- ICYMI

Here's what you need to know for Friday, March 2.

Using Market Softness to Add to Stocks Incrementally

Using Market Softness to Add to Stocks Incrementally

I think we'll probably see some shifting in the tariff policy over the weekend, giving the market some relief.

Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient In Phase 1 Trial Of Oral KORSUVA™

Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient In Phase 1 Trial Of Oral KORSUVA™

Study to evaluate Peptelligence®-Engineered Oral CR845 (CR845/difelikefalin) in Chronic Liver Disease Patients

Being Patient Until I Can Trust This Market More

Being Patient Until I Can Trust This Market More

It is very easy to force trades in this sort of environment.

Cara Therapeutics Doses First Patient In Phase 1 Trial Of Oral KORSUVA™ (CR845/difelikefalin) In Chronic Liver Disease (CLD) Patients

Cara Therapeutics Doses First Patient In Phase 1 Trial Of Oral KORSUVA™ (CR845/difelikefalin) In Chronic Liver Disease (CLD) Patients

Data to inform dose selection for planned Phase 2 trial in CLD-associated pruritus

Focused on Two Sectors

Focused on Two Sectors

If we have a little consolidating action here the buyers will start pushing again.

Indexes Are Holding Up Well, For Now

Indexes Are Holding Up Well, For Now

There are signs of stabilization, but the market is still digesting some very big swings.

The Character of the Market Has Shifted

The Character of the Market Has Shifted

The big question right now is to what degree should you be looking to take positions in individual stocks you may like.

8 Stocks That Are Ready to Change Direction

8 Stocks That Are Ready to Change Direction

These names are displaying bullish and bearish reversal patters over the last week.

How Trading Notes Can Increase Your Profits

How Trading Notes Can Increase Your Profits

Inertia is your biggest enemy in this market.

Commit To Buy Cara Therapeutics At $7.50, Earn 12.7% Using Options

Commit To Buy Cara Therapeutics At $7.50, Earn 12.7% Using Options

Investors eyeing a purchase of Cara Therapeutics Inc shares, but cautious about paying the going market price of $12.46/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2019 put at the $7.50 strike, which has a bid at the time of this writing of 95 cents.

Cara Therapeutics, Thomson Reuters, Wynn Resorts: 'Mad Money' Lightning Round

Cara Therapeutics, Thomson Reuters, Wynn Resorts: 'Mad Money' Lightning Round

Jim Cramer is bullish on Cara Therapeutics, Thomson Reuters, Wynn Resorts, and Edison International.

What's Holding Up This Market?: Cramer's 'Mad Money' Recap (Monday 12/11/17)

What's Holding Up This Market?: Cramer's 'Mad Money' Recap (Monday 12/11/17)

It's just very hard to keep stocks down in this environment, says Jim Cramer. It's part of a synchronized global expansion.

Cara Therapeutics Stock Sees Short Interest Decrease By 13.5%

Cara Therapeutics Stock Sees Short Interest Decrease By 13.5%

The most recent short interest data has been released for the 10/31/2017 settlement date, which shows a 1,149,738 share decrease in total short interest for Cara Therapeutics Inc , to 7,361,067, a decrease of 13.51% since 10/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Cara Therapeutics Reports Third Quarter 2017 Financial Results

Cara Therapeutics Reports Third Quarter 2017 Financial Results

Management to host conference call today at 4:30 p.m. ET

Cara Therapeutics Doses First Patient In Phase 1 Study Of Oral CR845 In Non-Hemodialysis Chronic Kidney Disease Patients

Cara Therapeutics Doses First Patient In Phase 1 Study Of Oral CR845 In Non-Hemodialysis Chronic Kidney Disease Patients

Study to inform dose selection and design of Phase 2 trial in non-hemodialysis patients with chronic kidney disease-associated pruritus (CKD-aP)

Cara Therapeutics Announces Participation In ANESTHESIOLOGY® 2017

Cara Therapeutics Announces Participation In ANESTHESIOLOGY® 2017

Data from respiratory safety trial of I.V. CR845 to be detailed in oral presentation